370 related articles for article (PubMed ID: 28329114)
1. PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia.
Bernelot Moens SJ; Neele AE; Kroon J; van der Valk FM; Van den Bossche J; Hoeksema MA; Hoogeveen RM; Schnitzler JG; Baccara-Dinet MT; Manvelian G; de Winther MPJ; Stroes ESG
Eur Heart J; 2017 May; 38(20):1584-1593. PubMed ID: 28329114
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players.
Marques P; Domingo E; Rubio A; Martinez-Hervás S; Ascaso JF; Piqueras L; Real JT; Sanz MJ
Biomed Pharmacother; 2022 Jan; 145():112460. PubMed ID: 34864314
[TBL] [Abstract][Full Text] [Related]
3. Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.
Gouni-Berthold I; Descamps OS; Fraass U; Hartfield E; Allcott K; Dent R; März W
Br J Clin Pharmacol; 2016 Dec; 82(6):1412-1443. PubMed ID: 27478094
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
[TBL] [Abstract][Full Text] [Related]
5. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
[TBL] [Abstract][Full Text] [Related]
6. Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia.
Pérez de Isla L; Ray KK; Watts GF; Santos RD; Alonso R; Muñiz-Grijalvo O; Diaz-Diaz JL; Badimon L; Catapano AL; Mata P
Atherosclerosis; 2019 Jul; 286():40-45. PubMed ID: 31100618
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and effectiveness of alirocumab and evolocumab in familial hypercholesterolemia (FH) in Belgium.
Snel M; Descamps OS
Acta Cardiol; 2024 May; 79(3):311-318. PubMed ID: 37767917
[No Abstract] [Full Text] [Related]
8. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
[TBL] [Abstract][Full Text] [Related]
9. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy.
Raal F; Panz V; Immelman A; Pilcher G
J Am Heart Assoc; 2013 Apr; 2(2):e000028. PubMed ID: 23537802
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis.
Peng W; Qiang F; Peng W; Qian Z; Ke Z; Yi L; Jian Z; Chongrong Q
Int J Cardiol; 2016 Nov; 222():119-129. PubMed ID: 27494723
[TBL] [Abstract][Full Text] [Related]
11. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
12. PCSK9: From discovery to therapeutic applications.
Farnier M
Arch Cardiovasc Dis; 2014 Jan; 107(1):58-66. PubMed ID: 24373748
[TBL] [Abstract][Full Text] [Related]
13. PCSK9 inhibitors.
Gencer B; Lambert G; Mach F
Swiss Med Wkly; 2015; 145():w14094. PubMed ID: 25856746
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA;
Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520
[TBL] [Abstract][Full Text] [Related]
15. Latest clinical evidence about the effect of PCSK9 monoclonal antibodies in patients with familial hypercholesterolaemia: an updated meta-analysis.
Zhang Q; Deng L; Chen C; Pan X; Jiang S
Endokrynol Pol; 2022; 73(1):110-120. PubMed ID: 35381104
[TBL] [Abstract][Full Text] [Related]
16. PCSK9 regulates the chemokine receptor CCR2 on monocytes.
Grune J; Meyborg H; Bezhaeva T; Kappert K; Hillmeister P; Kintscher U; Pieske B; Stawowy P
Biochem Biophys Res Commun; 2017 Apr; 485(2):312-318. PubMed ID: 28232185
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
Kastelein JJ; Hovingh GK; Langslet G; Baccara-Dinet MT; Gipe DA; Chaudhari U; Zhao J; Minini P; Farnier M
J Clin Lipidol; 2017; 11(1):195-203.e4. PubMed ID: 28391886
[TBL] [Abstract][Full Text] [Related]
18. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
[TBL] [Abstract][Full Text] [Related]
19. LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy.
Hamasaki M; Sakane N; Hara K; Kotani K
J Clin Lab Anal; 2021 Nov; 35(11):e24056. PubMed ID: 34652028
[TBL] [Abstract][Full Text] [Related]
20. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
